English

Wilson Therapeutics AB (publ) Interim Report January 1 – June 30, 2016

Report this content

Encouraging preliminary data from ongoing clinical trial

April 1 – June 30, 2016

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 26.9 M (loss: 16.7)
  • Loss per share, before and after dilution, totaled SEK 1.66 (loss: 13.14)
  • At June 30, cash and cash equivalents amounted to SEK 435.6 M (26.8)

January 1 – June 30, 2016

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 49.2 M (loss: 30.5)
  • Loss per share, before and after dilution, totaled SEK 5.86 (loss: 24.07)

Significant events during the period January 1 – June 30, 2016

  • A new share issue raised SEK 39.9 M after issue costs
  • Resolution regarding a 1:10 share split
  • Data from the ongoing Phase II trial of Decuprate®presented at major European conferences
  • Wilson Therapeutics was listed in the Mid Cap segment on Nasdaq Stockholm, raising SEK 402.7 M after issue costs
  • Ongoing phase II study fully enrolled
  • Rick Lilley appointed as Chief Regulatory Officer

Significant events after the end of the reporting period

  • Vincent Metzler appointed as Vice President Commercial Planning & Launch Strategy

       
”Data from our ongoing phase II trial continue to indicate that Decuprate® has the potential to address the unmet medical needs in Wilson Disease. Although the results are promising it is important to underline that these results are preliminary as the study is still ongoing but it will be very exciting to follow the trial completion during the end of the year.”
  
Jonas Hansson, CEO, Wilson Therapeutics.
  
  
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

More information is available at www.wilsontherapeutics.com.
  
  
For further information contact: 
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wilsontx.eu
  
Wilson Therapeutics AB (publ)
Corp. Reg. No. 556893-0357
Västra Trädgårdsgatan 15
SE-111 53 Stockholm, Sweden
   
  
The information in the interim report is such that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication on August 18, 2016 at 8:00 a.m. CET.

Tags:

Wilson Therapeutics Q2 2016

Documents & Links